This story has been updated with information from a conference call with NeoGenomics executives discussing the financial results.
NEW YORK – NeoGenomics Tuesday reported a 14 percent year-over-year decline in its second quarter revenues due to fallout from the COVID-19 pandemic.
For the three months ended June 30, total revenues reached $87.0 million, down from $101.7 million in Q2 2019, and slightly beating analysts' average estimate of $86.6 million.